Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers (CE sequencers). This collaboration stems from the outcomes of joint research conducted since the signing of a feasibility study (FS) agreement in August 2023, which focused on creating new genetic testing systems. The goal of Sysmex and Hitachi High-Tech is to produce genetic testing systems that are more efficient and cost-effective, thereby facilitating the widespread clinical application of personalized genetic testing for various diseases.

The field of genetic testing has seen significant advancements in assay reagent development using next-generation sequencing (NGS). However, there are challenges such as reducing measurement times and operational costs, underscoring the need for novel genetic testing systems suitable for widespread clinical use. To address these challenges, the companies signed the FS agreement in August 2023. The agreement aimed at exploring the development of new genetic testing systems that could offer optimal genetic analysis for individual diseases. This would be achieved by combining Hitachi High-Tech’s CE sequencer technology with Sysmex’s expertise in NGS reagent development and analysis technology, both honed through the advancement of genomic medicine in clinical settings.

Having met the objectives outlined in the FS agreement, Sysmex and Hitachi High-Tech have now agreed to proceed with the development of genetic testing systems intended for broad clinical use. Hitachi High-Tech will focus on obtaining medical device approvals for their CE sequencers, while Sysmex will develop and seek regulatory approvals for testing reagents compatible with these devices, as well as developing analysis software. Initially, the collaboration will concentrate on applications in oncology before gradually extending to other disease areas. By leveraging each company’s unique technologies and expertise, Sysmex and Hitachi High-Tech aim to promote the adoption of new genetic testing systems that offer shorter measurement durations and reduced operational costs.

Related Links:
Sysmex Corporation
Hitachi High-Tech Corporation

Visit expo >

Platinum Member

COVID-19 Rapid Test

OSOM COVID-19 Antigen Rapid Test

Magnetic Bead Separation Modules
MAG and HEATMAG

Anti-Cyclic Citrullinated Peptide Test

GPP-100 Anti-CCP Kit

Gold Member

Systemic Autoimmune Testing Assay

BioPlex 2200 ANA Screen with MDSS